108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy

Although the optimal sequential treatment (neoadjuvant therapy [NA] vs upfront surgery) for patients (pts) with cT1-2 cN0 HER2+ is unknown, previous studies suggest that NA is associated with lower rates of pN+ compared to those undergoing upfront surgery. Here, we evaluated the incidence of pathologic nodal disease in cT1-2 cN0 HER2+ pts treated with upfront surgery vs NA at 2 major academic hospitals in Spain.